Drugs / RLYB212
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06435845 | Nov 2024 → Oct 2025 | fetal and neonatal alloimmune thrombocytopenia | Rallybio | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLYB212 | “This study is a single-arm, open-label, multicenter study of RLYB212 in HPA-1b/b pregnant participants at higher risk for the occurrence of HPA-1a alloimmunization and FNAIT.” NCT06435845 ↗ |
| Modality | Monoclonal antibody | “human monoclonal anti-human platelet antigen (HPA)-1a immunoglobulin G antibody” NCT06435845 ↗ |
| Route | Subcutaneous | “RLYB212 Subcutaneous injection” NCT06435845 ↗ |